Clear All
785 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Chlorotrianisene Anisene 12 mg Hormonal Therapy Estrogen Yes 1992 1997 In Use
J1260 Dolasetron Mesylate Anzemet 10 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 1997 Jan 1, 2000 In Use
NA Alitretinoin Panretin 0.10% Hormonal Therapy Immunomodulator Retinoic Acid Derivative No 1999 In Use
N/A Imlunestrant Inluriyo 200mg Hormonal Therapy Estrogen Receptor Antagonist ER⍺ Yes 2025 In Use
NA Abemaciclib Verzenio 200 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
J9345 Retifanlimab-dlwr Zynyz 1mg Immunotherapy Checkpoint Inhibitor PD-1 No 2023 Aug 28, 2023 In Use
NA Erlotinib Tarceva 25 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2004 In Use
Q2043 Sipuleucel-T Provenge 1 dose = minimum of 50 million autologous cd54+ cells activated with pap-gm-csf Immunotherapy Immunomodulator Prostatic Acid Phosphatase No 2010 Jul 1, 2011 In Use
NA Enasidenib mesylate Idhifa 100 mg Chemotherapy Enzyme Inhibitor IDH2 Yes 2017 In Use
NA Axitinib Axitinib 1 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
J2353 octreotide sandostatin LAR 1 mg Hormonal Therapy Somatostatin Analog No 1998 Jan 1, 2004 In Use
J9144 Daratumumab, hyaluronidase-fihj Darzalex Faspro 10mg Immunotherapy Monoclonal Antibody CD38 No 2020 Jan 1, 2021 In Use
NA Imatinib mesylate Gleevec 400 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2001 In Use
J1954 Leuprolide acetate for depot suspension (lutrate depot) Lutrate Depot 7.5mg Hormonal Therapy GnRH Agonist No 2022 Apr 1, 2023 In Use
J1950 Leuprolide Acetate Eligard, Lupron Depot, Viadur, Lupron 3.75 mg Hormonal Therapy GnRH Agonist No 1989 Jan 1, 1997 In Use
NA Dutasteride Avodart 0.5mg Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Yes 2002 In Use
J9311 Rituximab and Hyaluronidase Rituxan Hycela 10mg Immunotherapy Monoclonal Antibody CD20 No 2017 Jan 1, 2019 In Use
Vorasidenib Voranigo 10mg,40mg Chemotherapy IDH Inhibitor IDH1, IDH2 Yes 2024 In Use
NA Anagrelide Agrylin 1mg Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Yes 1997 In Use
J1930 Lanreotide Acetate Somatuline Depot 1 mg Hormonal Therapy Somatostatin Analog No 2007 Jan 1, 2009 In Use
J1436 Etidronate Disodium Didronel 300 mg Ancillary Therapy Bisphosphonate No 1977 Jan 1, 1990 In Use
NA Gardasil-9 Human papillomavirus vaccine Ancillary Therapy Protective Agent HPV Vaccine No 2016 In Use
J9017 Arsenic Trioxide Trisenox 1 mg Chemotherapy Miscellaneous Agent PML/RARa No 2000 Jan 1, 2002 In Use
J9275 Cosibelimab-ipdl UNLOXCYT 2mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2025 Jul 9, 2025 In Use
J9048 Bortezomib (Fresniuskab) Bortezomib (Fresniuskab) 0.1mg Chemotherapy Proteasome Inhibitor 26S No 2017 Dec 21, 2022 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.